206 related articles for article (PubMed ID: 38160620)
1. Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses.
He Y; Zhou J; Gao H; Liu C; Zhan P; Liu X
Eur J Med Chem; 2024 Feb; 265():116069. PubMed ID: 38160620
[TBL] [Abstract][Full Text] [Related]
2. Medicinal chemistry strategies toward host targeting antiviral agents.
Ji X; Li Z
Med Res Rev; 2020 Sep; 40(5):1519-1557. PubMed ID: 32060956
[TBL] [Abstract][Full Text] [Related]
3. A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses.
Zheng Y; Li S; Song K; Ye J; Li W; Zhong Y; Feng Z; Liang S; Cai Z; Xu K
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632670
[TBL] [Abstract][Full Text] [Related]
4. Broad-spectrum Respiratory Virus Entry Inhibitors.
Zhao H; Yuen KY
Adv Exp Med Biol; 2022; 1366():137-153. PubMed ID: 35412139
[TBL] [Abstract][Full Text] [Related]
5. The future of antivirals: broad-spectrum inhibitors.
Debing Y; Neyts J; Delang L
Curr Opin Infect Dis; 2015 Dec; 28(6):596-602. PubMed ID: 26524332
[TBL] [Abstract][Full Text] [Related]
6. New pharmacological strategies to fight enveloped viruses.
Wisskirchen K; Lucifora J; Michler T; Protzer U
Trends Pharmacol Sci; 2014 Sep; 35(9):470-8. PubMed ID: 25108320
[TBL] [Abstract][Full Text] [Related]
7. Current progress in antiviral strategies.
Lou Z; Sun Y; Rao Z
Trends Pharmacol Sci; 2014 Feb; 35(2):86-102. PubMed ID: 24439476
[TBL] [Abstract][Full Text] [Related]
8. Preclinical discovery and development of maraviroc for the treatment of HIV.
Veljkovic N; Vucicevic J; Tassini S; Glisic S; Veljkovic V; Radi M
Expert Opin Drug Discov; 2015 Jun; 10(6):671-84. PubMed ID: 25927601
[TBL] [Abstract][Full Text] [Related]
9. Broad-spectrum antivirals against viral fusion.
Vigant F; Santos NC; Lee B
Nat Rev Microbiol; 2015 Jul; 13(7):426-37. PubMed ID: 26075364
[TBL] [Abstract][Full Text] [Related]
10. Labyrinthopeptins Exert Broad-Spectrum Antiviral Activity through Lipid-Binding-Mediated Virolysis.
Prochnow H; Rox K; Birudukota NVS; Weichert L; Hotop SK; Klahn P; Mohr K; Franz S; Banda DH; Blockus S; Schreiber J; Haid S; Oeyen M; Martinez JP; Süssmuth RD; Wink J; Meyerhans A; Goffinet C; Messerle M; Schulz TF; Kröger A; Schols D; Pietschmann T; Brönstrup M
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666384
[TBL] [Abstract][Full Text] [Related]
11. Biomolecular Condensates as Novel Antiviral Targets.
Martin EW; Iserman C; Olety B; Mitrea DM; Klein IA
J Mol Biol; 2024 Feb; 436(4):168380. PubMed ID: 38061626
[TBL] [Abstract][Full Text] [Related]
12. Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses.
Lu S; Pan X; Chen D; Xie X; Wu Y; Shang W; Jiang X; Sun Y; Fan S; He J
Bioorg Chem; 2021 Feb; 107():104619. PubMed ID: 33450541
[TBL] [Abstract][Full Text] [Related]
13. Intervention strategies for emerging viruses: use of antivirals.
Debing Y; Jochmans D; Neyts J
Curr Opin Virol; 2013 Apr; 3(2):217-24. PubMed ID: 23562753
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activity of cationic amphiphilic drugs.
Salata C; Calistri A; Parolin C; Baritussio A; Palù G
Expert Rev Anti Infect Ther; 2017 May; 15(5):483-492. PubMed ID: 28286997
[TBL] [Abstract][Full Text] [Related]
15. Antivirals with common targets against highly pathogenic viruses.
Lu L; Su S; Yang H; Jiang S
Cell; 2021 Mar; 184(6):1604-1620. PubMed ID: 33740455
[TBL] [Abstract][Full Text] [Related]
16. Assessing the potential of repurposing ion channel inhibitors to treat emerging viral diseases and the role of this host factor in virus replication.
Russell T; Gangotia D; Barry G
Biomed Pharmacother; 2022 Dec; 156():113850. PubMed ID: 36411658
[TBL] [Abstract][Full Text] [Related]
17. Kinase Inhibitors as Underexplored Antiviral Agents.
García-Cárceles J; Caballero E; Gil C; Martínez A
J Med Chem; 2022 Jan; 65(2):935-954. PubMed ID: 33970631
[TBL] [Abstract][Full Text] [Related]
18. Targeting viral entry as a strategy for broad-spectrum antivirals.
Mazzon M; Marsh M
F1000Res; 2019; 8():. PubMed ID: 31559009
[TBL] [Abstract][Full Text] [Related]
19. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
20. Advances in the development of entry inhibitors for sialic-acid-targeting viruses.
Heida R; Bhide YC; Gasbarri M; Kocabiyik Ö; Stellacci F; Huckriede ALW; Hinrichs WLJ; Frijlink HW
Drug Discov Today; 2021 Jan; 26(1):122-137. PubMed ID: 33099021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
